A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)

NCT00500682 | Completed Phase 3 Results DMC

• 1 other identifier: KRM-306
• Study Type: interventional
• Target: 1,020
• Locations: 12 countries
• Sites: 105

Brief Summary

1\) To evaluate the effectiveness of AST-120 (spherical carbon adsorbent) added to standard-of-care therapy in moderate to severe Chronic Kidney Disease (CKD), on time to first occurrence of any event of the triple composite outcome of initiation of dialysis, kidney transplant or doubling of serum creatinine (sCr) when compared with placebo; 2) To evaluate the safety and tolerability of long-term AST-120 therapy in patients with CKD; 3) To evaluate the effects of AST-120 versus placebo, on other measures of renal function.

Conditions

Chronic Kidney Disease

Keywords

Kidney Diseases

Outcome Measures

Primary Outcomes (2)

• Composite of Dialysis Initiation, Kidney Transplantation, and Serum Creatinine Doubling. Number of Participants Meeting the Criteria Are Reported.

  Beyond Week 48, a 12-week visit cycle continued until the end of the study or until individual patients reached an endpoint

• Number of Participants With Treatment-emergent Adverse Events and Treatment-emergent Serious Adverse Events

  Approximately 42 months

Secondary Outcomes (7)

• Number of Participants Who Developed a Component of a Quadruple Composite Endpoint (Initiation of Dialysis, Kidney Transplant, Doubling of sCr, or Death)

  Approximately 42 months

• Vitamin A Levels

  Baseline, Week 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, Early Term/Discontinuation (Mean: 428.615 Days), Final Visit (Mean: 947.354 Days)

• Vitamin B12 Levels

  Baseline, Week 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, Early Term/Discontinuation (Mean: 428.114 Days), Final Visit (Mean: 947.239 Days)

• 25-Hydroxyvitamin D Levels

  Baseline, Week 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, Early Term/Discontinuation (Mean: 427.270 Days), Final Visit (Mean: 946.762 Days)

• Vitamin E Levels

  Baseline, Week 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, Early Term/Discontinuation (Mean: 428.056 Days), Final Visit (Mean: 946.525 Days)

Study Arms (2)

Placebo

PLACEBO COMPARATOR

Drug: Placebo

AST-120

EXPERIMENTAL

Drug: AST-120

Interventions

Placebo DRUG

9g /day (3 times a day)

Placebo

AST-120 DRUG

9g /day (3 times a day)

AST-120

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18 years or older
• Moderate to severe CKD, not anticipated to require dialysis or renal transplant within the next 6 months
• Patient survival expected to be no less than one year
• Serum creatinine in men \>= 2.0 mg/dL (\>= 177 µmol/L) and \<= 5.0 mg/dL (\<= 442 µmol/L), and in women \>= 1.5 mg/dL (\>= 133 µmol/L) and \<= 5.0 mg/dL (\<= 442 µmol/L) at Screening
• Urinary total protein to urinary total creatinine ratio must be \>= 0.5 on a spot void at Screening
• Blood pressure \<= 160/90 mmHg at both Screening and Baseline. In addition, blood pressure, if measured, must have been stable in hypertensive patients over the 3 months prior to Screening, with no more than 1 blood pressure reading \> 160/90 mmHg
• In patients being treated for hypertension, they should be on a stable anti-hypertensive regimen

You may not qualify if:

• Obstructive or reversible cause of kidney disease
• Nephrotic syndrome defined as a ratio of urinary total protein to urinary creatinine of \> 6.0 as measured on a spot void
• Adult polycystic kidney disease
• History of previous kidney transplant
• History of recent (within the past 6 months) accelerated or malignant hypertension
• Uncontrolled arrhythmia or severe cardiac disease within the past 6 months
• History of malabsorption, inflammatory bowel disease, hiatal hernia, active peptic ulcer, or severe GI dysmotility, not attributable to the use of a phosphate binder
• Received any investigational agent or participated in a clinical study within the previous 3 months
• Presence of any significant medical condition that might create an undue risk with study participation, or significantly confound the collection of safety and efficacy data in this study

Sponsors & Collaborators

• Tanabe Pharma Corporation: lead
• Kureha Corporation: collaborator

Study Sites (105)

Unknown Facility

Phoenix, Arizona, United States

Location

Unknown Facility

Little Rock, Arkansas, United States

Location

Unknown Facility

Alhambra, California, United States

Location

Unknown Facility

Covina, California, United States

Location

Unknown Facility

Glendale, California, United States

Location

Unknown Facility

Los Angeles, California, United States

Location

Unknown Facility

Stamford, Connecticut, United States

Location

Unknown Facility

Washington D.C., District of Columbia, United States

Location

Unknown Facility

Hudson, Florida, United States

Location

Unknown Facility

Miami, Florida, United States

Location

Unknown Facility

Ocala, Florida, United States

Location

Unknown Facility

Orlando, Florida, United States

Location

Unknown Facility

Pembroke Pines, Florida, United States

Location

Unknown Facility

Spring Hill, Florida, United States

Location

Unknown Facility

Tampa, Florida, United States

Location

Unknown Facility

Winter Park, Florida, United States

Location

Unknown Facility

Kansas City, Kansas, United States

Location

Unknown Facility

New Orleans, Louisiana, United States

Location

Unknown Facility

Shreveport, Louisiana, United States

Location

Unknown Facility

Ypsilanti, Michigan, United States

Location

Unknown Facility

Kansas City, Missouri, United States

Location

Unknown Facility

St Louis, Missouri, United States

Location

Unknown Facility

Camden, New Jersey, United States

Location

Unknown Facility

Eatontown, New Jersey, United States

Location

Unknown Facility

Port Washington, New York, United States

Location

Unknown Facility

Springfield Gardens, New York, United States

Location

Unknown Facility

Asheville, North Carolina, United States

Location

Unknown Facility

Cincinnati, Ohio, United States

Location

Unknown Facility

Dayton, Ohio, United States

Location

Unknown Facility

Toledo, Ohio, United States

Location

Unknown Facility

Portland, Oregon, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, United States

Location

Unknown Facility

Pittsburgh, Pennsylvania, United States

Location

Unknown Facility

Rock Hill, South Carolina, United States

Location

Unknown Facility

Nashville, Tennessee, United States

Location

Unknown Facility

Arlington, Texas, United States

Location

Unknown Facility

Dallas, Texas, United States

Location

Unknown Facility

Houston, Texas, United States

Location

Unknown Facility

San Antonio, Texas, United States

Location

Unknown Facility

Appleton, Wisconsin, United States

Location

Unknown Facility

Oshkosh, Wisconsin, United States

Location

Unknown Facility

Buenos Aires, Argentina

Location

Unknown Facility

Córdoba, Argentina

Location

Unknown Facility

San Luis, Argentina

Location

Unknown Facility

San Miguel de Tucumán, Argentina

Location

Unknown Facility

San Pedro, Argentina

Location

Unknown Facility

Barao Geraldo-Campinas, Brazil

Location

Unknown Facility

Belo Horizonte Minas Gerais, Brazil

Location

Unknown Facility

Juiz de Fora, Brazil

Location

Unknown Facility

Porto Alegre, Brazil

Location

Unknown Facility

Rio de Janeiro, Brazil

Location

Unknown Facility

São Paulo, Brazil

Location

Unknown Facility

Taubaté, Brazil

Location

Unknown Facility

Winnipeg, Manitoba, Canada

Location

Unknown Facility

Brampton, Ontario, Canada

Location

Unknown Facility

Kitzhener, Ontario, Canada

Location

Unknown Facility

Oakville, Ontario, Canada

Location

Unknown Facility

Scarborough Village, Ontario, Canada

Location

Unknown Facility

Toronto, Ontario, Canada

Location

Unknown Facility

Montreal, Quebec, Canada

Location

Unknown Facility

České Budějovice, Czechia

Location

Unknown Facility

Jihlava, Czechia

Location

Unknown Facility

Ostrava - Poruba, Czechia

Location

Unknown Facility

Prague, Czechia

Location

Unknown Facility

Tábor, Czechia

Location

Unknown Facility

Grenoble, France

Location

Unknown Facility

Lyon, France

Location

Unknown Facility

Nantes, France

Location

Unknown Facility

Saint-Lô, France

Location

Unknown Facility

Bologna, Italy

Location

Unknown Facility

Brescia, Italy

Location

Unknown Facility

Como, Italy

Location

Unknown Facility

Pavia, Italy

Location

Unknown Facility

Aguascalientes, Mexico

Location

Unknown Facility

Mexico City, Mexico

Location

Unknown Facility

Tijuana, Mexico

Location

Unknown Facility

Gdansk, Poland

Location

Unknown Facility

Szczecin, Poland

Location

Unknown Facility

Torun, Poland

Location

Unknown Facility

Warsaw, Poland

Location

Unknown Facility

Caguas, Puerto Rico

Location

Unknown Facility

Bamaul, Russia

Location

Unknown Facility

Kazan', Russia

Location

Unknown Facility

Krasnodar, Russia

Location

Unknown Facility

Moscow, Russia

Location

Unknown Facility

Nizhny Novgorod, Russia

Location

Unknown Facility

Novosibirsk, Russia

Location

Unknown Facility

Pyatigorsk, Russia

Location

Unknown Facility

Ryazan, Russia

Location

Unknown Facility

Saint Petersburg, Russia

Location

Unknown Facility

Saratov, Russia

Location

Unknown Facility

Smolensk, Russia

Location

Unknown Facility

Sochi, Russia

Location

Unknown Facility

Stavropol, Russia

Location

Unknown Facility

Yekaterinburg, Russia

Location

Unknown Facility

Chernivtsi, Ukraine

Location

Unknown Facility

Dnipropetrovsk, Ukraine

Location

Unknown Facility

Donetsk, Ukraine

Location

Unknown Facility

Ivano-Frankivsk, Ukraine

Location

Unknown Facility

Kharkiv, Ukraine

Location

Unknown Facility

Kiev, Ukraine

Location

Unknown Facility

Odesa, Ukraine

Location

Unknown Facility

Uzhhorod, Ukraine

Location

Unknown Facility

Vinnitsa, Ukraine

Location

Unknown Facility

Zhytomyr, Ukraine

Location

Related Publications (3)

• Schulman G, Berl T, Beck GJ, Remuzzi G, Ritz E, Arita K, Kato A, Shimizu M. Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD. J Am Soc Nephrol. 2015 Jul;26(7):1732-46. doi: 10.1681/ASN.2014010042. Epub 2014 Oct 27.

  PMID: 25349205 RESULT

• Schulman G, Berl T, Beck GJ, Remuzzi G, Ritz E, Shimizu M, Kikuchi M, Shobu Y. Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120. Clin Exp Nephrol. 2018 Apr;22(2):299-308. doi: 10.1007/s10157-017-1447-0. Epub 2017 Jul 24.

  PMID: 28741050 DERIVED

• Schulman G, Berl T, Beck GJ, Remuzzi G, Ritz E, Shimizu M, Shobu Y, Kikuchi M. The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials. BMC Nephrol. 2016 Sep 30;17(1):141. doi: 10.1186/s12882-016-0357-9.

  PMID: 27716149 DERIVED

MeSH Terms

Conditions

Renal Insufficiency, Chronic; Kidney Diseases

Interventions

AST 120

Condition Hierarchy (Ancestors)

Renal Insufficiency; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Results Point of Contact

• Title: Clinical Trials, Information Desk
• Organization: Tanabe Pharma Corporation

cti-inq-ml.JP@ml.tanabe-pharma.com

Study Officials

• Professor

  Information at Mitsubishi Tanabe Pharma Development America, Inc.

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 11, 2007
• First Posted: July 13, 2007
• Study Start: July 1, 2007
• Primary Completion: October 1, 2011
• Study Completion: October 1, 2011
• Last Updated: January 8, 2026
• Results First Posted: March 2, 2015

Record last verified: 2025-12

Locations

US (41); AR (5); ME (3); CA (7); BR (7); PR (1); FR (4); CZ (5); IT (4); RU (14); PL (4); UA (10)